Clorox's Q4 Call: Flat EPS Masks a 520-Basis-Point Margin Hit and a Fresh Start

Clorox Q4: stable EPS masked much weaker underlying results

The headline number looked calm. Clorox posted adjusted EPS of $1.66, exactly in line with expectations. But the quarter was much weaker underneath the surface: the core business softened sharply, and gross margin took a serious hit.

What the in-line EPS concealed

Reported sales fell 2% to $1.95 billion, but that understates the weakness because GOJO added about 10 points to reported growth. On an organic basis, sales still fell 13%. That makes this less a story about normal operations and more a story about a shrinking core business.

The bigger warning sign was profitability. Gross margin fell 520 basis points to 41.3%, reflecting pressure from lower volume, the GOJO inventory step-up, higher commodity costs, and higher manufacturing and logistics costs.

This quarter reads better as a reset than as evidence of a healthy business. The next call should show whether the core business is stabilizing.

The organic sales drop was largely a comparison issue, but the margin pressure was real

ERP comparison explains most of the organic decline

Management said organic sales fell primarily due to lapping the incremental shipments related to the ERP transition, which was about 13.5 points. That suggests the low base was shaped largely by timing in the prior year rather than by an abrupt break in household demand.

Margin compression showed the quarter still had substance

Sales mechanics do not fully explain the profit squeeze. In Q3, gross margin was still under pressure, but far less so, down 140 basis points to 43.2%. The move from a 140-bps hit to a 520-bps hit in Q4 suggests multiple pressures converged in the year-end quarter.

Why the reset also created a cleaner setup

Clorox's U.S. ERP implementation is now complete. That does not erase the Q4 damage, but it does remove one source of future strain. As one market reading of the reset put it, the earlier transition had created roughly a $0.90 drag on FY26 EPS, while the payoff includes removing about $0.37 of annual EPS drag from extra IT costs starting in FY27.

The debate: one-time cleanup or a longer repair job?

Why the bullish view still exists

Bulls can argue that Q4 was unusual for a few reasons:

• The organic sales comparison was heavily weighed down by the ERP-related shipment timing.
• Q3 was already better than Q4, which suggests the pressure may not be getting worse.
• With the ERP overhaul finished, one future source of strain should no longer carry into the next period.

Why investors should still be cautious

Bears focus on different risks:

• GOJO is not automatically a margin positive. Q4 gross margin was hit by the inventory step-up tied to the acquisition, and Q3 still included costs associated with the acquisition of GOJO Industries.
• A better Q3 does not yet prove a turnaround. Gross margin was still under pressure in Q3.
• Clorox still has to show that the reset is producing operating leverage, not just a easier comparison.

What matters on Nov. 2

Executives report again on Nov. 2, 2026. The key questions are straightforward:

• Does organic sales commentary look healthier once the ERP comparison fades?
• Does gross margin keep improving from the Q4 low?
• Does GOJO integration start to look more like growth support than ongoing execution friction?

What to watch in the next Clorox update

Investors do not need a dramatic recovery story right away. They need proof that Q4 was a cleanup quarter, not the new normal.

Three signals to monitor

• Organic sales: The test is whether the drag from lapping the incremental shipments related to the ERP transition stops dominating the narrative and demand looks cleaner.
• Gross margin: After the recent gross margin decreased 520 basis points to 41.3% squeeze, the next priority is stabilization and then improvement.
• GOJO contribution: Clorox has completed the acquisition of GOJO, but investors still need evidence the business can do more than add revenue, especially with costs associated with the acquisition of GOJO Industries still part of the picture.

If sales normalize without margin recovery, the bull case weakens. If both improve together, the case for a true reset becomes much stronger.